The Centres of Excellence for Commercialization and Research framework (CECR) enabled PC-TRiADD to build a solid foundation and gain momentum toward our objectives.  Since our inception in 2008, we have:

  • Attracted over $18 million in research contracts and $92.1 million in peer-reviewed funding, through the structuring of our core platforms to form an integrated contract research enterprise
  • Expanded High Quality Personnel and management to include an experienced executive team
  • Expanded our portfolio of IP protected targets and drug candidates that tackle treatment resistance that are translating into commercialization activities, with 277 patents filed/issued
  • Established 9 licensing agreements of IP with industry (8 drug, 1 biomarker)
  • Attracted increased global funding allowing us to initiate 125 new clinical trials, the majority of which are either peer reviewed, grant funded or are sponsored by pharmaceutical companies